Drugs / COVID-HIGIV
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04661839 | Dec 2020 → Jul 2021 | COVID-19 | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04910269 | Aug 2021 → May 2026 | COVID-19 | University of Minnesota | Suspended | No outcome recorded |
| Phase 3 | NCT04546581 | Oct 2020 → May 2021 | COVID-19, severe acute respiratory syndrome | University of Minnesota | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-HIGIV | “We have developed an anti-SARS-CoV-2 immunoglobulin intravenous (Human) (COVID-HIGIV), a potential improvement from using convalescent plasma.” PMID 36216961 ↗ Oct 2022 |
| Known as | anti-SARS-CoV-2 immunoglobulin intravenous (Human) | “We have developed an anti-SARS-CoV-2 immunoglobulin intravenous (Human) (COVID-HIGIV), a potential improvement from using convalescent plasma.” PMID 36216961 ↗ Oct 2022 |
| Action | Inhibit | “more concentrated neutralizing antibody activity” PMID 33715160 ↗ Mar 2021 |
| Modality | Protein / enzyme biologic | “a highly purified immunoglobulin G (IgG) product” PMID 33715160 ↗ Mar 2021 |
| Route | Intravenous | “anti-SARS-CoV-2 immunoglobulin intravenous (Human)” PMID 36216961 ↗ Oct 2022 |